Mucinex

PreclinicalSmall molecule

RReckitt Benckiser LLC

Mucinex is one of 54 small molecule programs targeting Respiratory tract infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

KeratitisActive, not recruiting

Respiratory Tract InfectionPhase 2/Phase 3

Active, not recruiting

KeratitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Respiratory Tract Infection

#DrugCompanyPhaseTrials

Tylenol

KKenvue Brands

Approved

1 2

Levaquin

WWim Janssens

Approved

—3

Tobrex

VViatris Specialty LLC

Approved

—4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

1 6

Quietus

Merck & Co.

Phase 2

1 7

Veklury

Gilead

Phase 2

1 8

Rapivab

BBioCryst Pharmaceuticals

Phase 3

1 9

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 10

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics2 trials

Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers

Completed·RReckitt Benckiser LLC·Phase 1·NCT03644108·30 enrolled

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

Completed·RReckitt Benckiser LLC·Phase 1·NCT03633487·24 enrolled

Respiratory Infection1 trial

Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

Completed·RReckitt Benckiser LLC·Phase 2·NCT01114581·38 enrolled

Respiratory tract infection1 trial

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Completed·RReckitt Benckiser LLC·Phase 2/3·NCT01537081·2,810 enrolled

MPA1 trial

Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers

Completed·RReckitt Benckiser LLC·Phase 1·NCT03644095·30 enrolled

Keratitis1 trial

Mucinex® for Treatment of Filamentary Keratitis

Completed·MMassachusetts Eye and Ear Infirmary·N/A·NCT02859246·15 enrolled

4 more indications

Treatment1 trial

Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion

Completed·RReckitt Benckiser LLC·Phase 4·NCT03725085·552 enrolled

Cough1 trial

Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00902707·12 enrolled

Fed1 trial

Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted

Completed·RReckitt Benckiser LLC·Phase 1·NCT03649750·36 enrolled

Unspecified1 trial

Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h

Completed·RReckitt Benckiser LLC·Phase 1·NCT03642262·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Mucinex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mucinex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mucinex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Reckitt Benckiser LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RReckitt Benckiser LLC

Mucinex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics2 trials

Respiratory Infection1 trial

Respiratory tract infection1 trial

MPA1 trial

Keratitis1 trial

Treatment1 trial

Cough1 trial

Fed1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News